文献速递妇科肿瘤支持与姑息治疗消化系统肿瘤

纳武利尤单抗联合伊匹木单抗治疗晚期dMMR/MSI-H非结直肠癌:非随机临床试验

Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-01-01

MOST-CIRCUIT前瞻性多中心非随机2期试验纳入52例晚期dMMR/MSI-H非结直肠癌患者,评估纳武利尤单抗联合伊匹木单抗的疗效与安全性。客观缓解率为63%(95%CI 50%-75%),6个月无进展生存率为71%(95%CI 57%-81%),23%患者发生3/4级免疫相关不良事件。联合阻断可能成为该人群单药治疗的替代选择。

要点

  • 纳武利尤单抗联合伊匹木单抗在晚期dMMR/MSI-H非结直肠癌中客观缓解率达63%。
  • 6个月无进展生存率为71%,中位缓解持续时间未达到,79%的缓解持续中。
  • 23%患者发生3/4级免疫相关不良事件,需关注毒性管理。

核心结论

  • 纳武利尤单抗联合伊匹木单抗在晚期dMMR/MSI-H非结直肠癌中与高比例持久缓解相关,优于已发表的抗PD-1/PD-L1单药试验,可能作为单药治疗的替代选择。

研究设计与样本

  • MOST-CIRCUIT前瞻性多中心非随机2期临床试验,纳入52例晚期dMMR/MSI-H非结直肠癌患者(队列D),2021年8月至2024年2月从17个澳大利亚和新西兰中心入组,分析于2025年5月进行。

主要发现

  • 客观缓解率为63%(95%CI 50%-75%),中位缓解持续时间未达到,79%的缓解仍在持续。
  • 中位无进展生存期和总生存期未达到,6个月无进展生存率为71%(95%CI 57%-81%)。
  • 12例(23%)患者发生3/4级免疫相关不良事件。

临床怎么用

  • 对于晚期dMMR/MSI-H非结直肠癌患者,尤其是子宫内膜癌等常见类型,可考虑纳武利尤单抗联合伊匹木单抗作为治疗选择。
  • 治疗期间需密切监测免疫相关不良事件,3/4级发生率为23%。

局限性

  • 非随机设计,样本量较小(52例),随访时间有限,中位无进展生存期和总生存期尚未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) cancers constitute one of the most immunogenic tumors. Anti-programmed cell death 1 (PD-1) monotherapy provides durable responses in a third of patients with advanced dMMR/MSI-H noncolorectal cancers. Combined anti-PD-1/cytotoxic lymphocyte antigen 4 (CTLA-4) blockade using nivolumab and ipilimumab has shown superiority to anti-PD-1 monotherapy in other immunogenic cancers such as metastatic melanoma. The Combination Immunotherapy in Rare Cancers Under Investigation (MOST-CIRCUIT) is the first trial that investigated combined anti-PD-1/CTLA-4 blockade in advanced dMMR/MSI-H noncolorectal cancers. OBJECTIVE: To evaluate the efficacy and safety of combined anti-PD-1/CTLA-4 blockade using nivolumab and ipilimumab in advanced dMMR/MSI-H noncolorectal cancers. DESIGN, SETTING, AND PARTICIPANTS: The MOST-CIRCUIT prospective multicenter nonrandomized phase 2 clinical trial enrolled 52 patients with advanced dMMR/MSI-H into cohort D. Patients were enrolled from August 2021 to February 2024 across 17 Australian and New Zealand sites. The analysis itself took place in May 2025. INTERVENTIONS: Patients received nivolumab, 3 mg/kg, and ipilimumab, 1 mg/kg, every 3 weeks for 4 doses, followed by nivolumab, 480 mg, every 4 weeks for 96 weeks, until disease progression or the development of unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The co-primary end points were objective response rate (ORR) and 6-month progression-free survival (6-PFS) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, with the secondary end points being median overall survival (mOS), progression-free survival (PFS), and treatment-related toxic effects. RESULTS: Overall, 52 participants were included. The median (range) age of participants was 62 (29-84) years; 41 (79%) were female individuals and 11 (21%) were male individuals. Overall, 52 patients representing 17 tumor types were enrolled, with the most common tumor type being endometrial cancer (26 [50%]). Twenty-seven patients (52%) were pretreated for metastatic disease. ORR was 63% (95% CI, 50% to 75%) with the median duration of response not being reached and 79% of responses being ongoing. The median PFS and OS have not been reached and the 6-month PFS was 71% (95% CI, 57%-81%). Overall, 12 patients (23%) experienced a grade 3/4 immune-related adverse event. CONCLUSIONS AND RELEVANCE: This nonrandomized clinical trial found that combined anti-PD-1/CTLA-4 blockade was associated with a high rate of durable responses in dMMR/MSI-H noncolorectal cancers, comparing favorably to published trials using anti-PD-1/programmed cell death ligand 1 monotherapy. Anti-PD-1/CTLA-4 blockade using nivolumab and ipilimumab may represent an alternative treatment option to monotherapy in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04969887.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Carlino MS, Gao B, Michael M, et al. Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial. JAMA Oncol. 2026. PMID: 41231502. doi:10.1001/jamaoncol.2025.4721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。